SciBX: Science-Business eXchange Contents: April 26 2012, Volume 5 / Issue 17

TABLE OF CONTENTS April 26 2012, Volume 5 / Issue 17 Analysis Cover Story Translational Notes Targets and Mechanisms The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine/metabolic disease Gastrointestinal disease Infectious disease Musculoskeletal disease Neurology The Distillery: Techniques Assays and screens Computational models Drug delivery Drug platforms Imaging Markers SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Cancer cell line encyclopedias Tim Fulmer doi:10.1038/scibx.2012.431 Two research teams have independently developed large-scale screening platforms to profile hundreds of human cancer cell lines and identify drug sensitivity biomarkers. Novartis, a member of one of the groups, is now using the platform to guide patient selection in Phase I cancer trials. Full Text | PDF Translational Notes Top Texas translation Lev Osherovich doi:10.1038/scibx.2012.432 The taxpayer-backed Cancer Prevention & Research Institute of Texas is moving downstream from its initial focus on basic research in oncology. This month, the institute announced its latest round of grants—this time focusing on both translational- and commercial-stage research, the latter of which includes recruiting companies to relocate to Texas. Full Text | PDF Targets and Mechanisms Top Pumping up the metabolic Rev-ERB Michael J. Haas doi:10.1038/scibx.2012.433 Two teams have shown that Rev-ERBAs play a central role in regulating the circadian clock and metabolism, and a third group has found that agonizing the receptors treated obesity in mice, suggesting Rev-ERBA agonists could help treat a range of metabolic diseases. Next, agonists with longer half-lives will need to be developed and patient populations that might benefit from the molecules will have to be identified. Full Text | PDF TAU's cease and de-cis-t letter Lauren Martz doi:10.1038/scibx.2012.434 Researchers at Harvard Medical School have developed isoform-specific antibodies to target phosphorylated TAU in Alzheimer's disease. The antibodies will need to be validated for early detection, treatment and prevention of the disease in patients. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Arachidonate 15-lipoxygenase (ALOX15; 15-LOX) doi:10.1038/scibx.2012.435 Mouse and cell culture studies suggest increasing 15-LOX activity could help prevent autoimmune diseases. Full Text | PDF Cancer Top Serine/threonine kinase 33 (STK33); heat shock protein 90 (Hsp90) doi:10.1038/scibx.2012.436 Studies in cell culture suggest blocking the interaction between STK33 and Hsp90 could help treat tumors driven by activating mutations in K-Ras. Full Text | PDF Phosphoinositide 3-kinase (PI3K) doi:10.1038/scibx.2012.437 Mouse and cell culture studies suggest inhibiting PI3K signaling could help improve the effects of ADI-PEG 20 in melanoma. Full Text | PDF Glutathione peroxidase 3 plasma (GPX3); tumor protein p53 inducible protein 3 (TP53I3; PIG3) doi:10.1038/scibx.2012.438 In vitro studies suggest increasing the activity of GPX3 and PIG3 could help treat prostate cancer. Full Text | PDF Cardiovascular disease Top MicroRNA-214 (miR-214) doi:10.1038/scibx.2012.439 Mouse studies suggest increasing miR-214 levels could help protect against cardiac ischemia/reperfusion injury. Full Text | PDF Endocrine/metabolic disease Top Inositol 1,4,5-triphosphate receptor (ITPR; IP3R) doi:10.1038/scibx.2012.440 Mouse studies suggest inhibiting IP3R could help treat diabetes. Full Text | PDF Gastrointestinal disease Top Ceramide doi:10.1038/scibx.2012.441 A study in mice identified an anticeramide antibody called 2A2 that could help prevent or reduce radiation-induced gastrointestinal syndrome. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2012.442 An in vitro study identified derivatives of the antifungal clotrimazole that could help treat leishmaniasis and Chagas disease. Full Text | PDF Dengue virus envelope protein E (DENV_gp1) doi:10.1038/scibx.2012.443 In vitro studies identified small molecule inhibitors of the viral fusion protein DENV_gp1 that could help treat Dengue fever. Full Text | PDF Musculoskeletal disease Top Heat shock 70 kDa protein 1A (Hsp72; HspA1) doi:10.1038/scibx.2012.444 Mouse studies suggest increasing Hsp72 activity could help treat muscular dystrophy. Full Text | PDF Neurology Top Not applicable doi:10.1038/scibx.2012.445 In vitro studies suggest gambierol analogs could help treat AD. Full Text | PDF Histone deacetylase 4 (HDAC4) doi:10.1038/scibx.2012.446 A study in mice suggests blocking the nuclear localization of HDAC4 may help treat ataxia telangiectasia, a neurodegenerative disease caused by mutation of ataxia telangiectasia mutated (ATM). Full Text | PDF Lysophosphatidic acid receptor 5 (LPAR5; LPA5) doi:10.1038/scibx.2012.447 Mouse studies suggest inhibiting LPAR5 could help treat neuropathic pain. Full Text | PDF Distillery: Techniques Assays and screens Top Comprehensive cell-line panel for predicting responses to cancer therapies doi:10.1038/scibx.2012.448 A collection of hundreds of cancer cell lines could help predict responses to cancer therapies. Full Text | PDF Comprehensive cell-line panel for predicting responses to cancer therapies doi:10.1038/scibx.2012.449 A collection of nearly 1,000 cancer cell lines could help predict responses to cancer therapies. Full Text | PDF Computational models Top Computational model for estimating intracranial pressure doi:10.1038/scibx.2012.450 A computational model for estimating intracranial pressure could improve the diagnosis of brain injuries. Full Text | PDF Drug delivery Top Dendrimer-based drug delivery to treat cerebral palsy doi:10.1038/scibx.2012.451 Studies in rabbits identified a dendrimer–small molecule conjugate that crossed the blood brain barrier and could help treat cerebral palsy. Full Text | PDF Drug platforms Top Controlled microfluidic formulation of small interfering RNA–containing lipid nanoparticles doi:10.1038/scibx.2012.452 Controlled microfluidic formulation of siRNA-containing lipid nanoparticles could aid the development of siRNA-based therapeutics. Full Text | PDF Imaging Top Brain tumor imaging via triple-modal MRI, photoacoustic and Raman nanoparticles doi:10.1038/scibx.2012.453 A triple-modality approach to imaging nanoparticles could help improve surgical resection of brain tumors. Full Text | PDF Markers Top Intercellular adhesion molecule-1 (ICAM-1; CD54) as a marker of treatment response for congenital disorders of glycosylation doi:10.1038/scibx.2012.454 Patient sample studies suggest ICAM-1 could be useful as a marker for congenital disorders of glycosylation, which are caused by inherited genetic defects in N-linked glycosylation. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.